Lucid Diagnostics Inc. LUCD NASDAQ

Lucid Diagnostics Inc. (LUCD) reported total assets of $40.45M and total liabilities of $29.51M for fiscal year 2025, resulting in total equity of $10.94M.

The company held $34.71B in cash and short-term investments. Total debt stood at $25.82B, with net debt of $-8.89B. The Debt-to-Equity (D/E) ratio was 2361.01 (leveraged).

Current ratio is 1.31, suggesting adequate short-term liquidity. Interest coverage is -2256.4x (weak).

Criteria supported by this page:

• HEALTH (17/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
• MOAT (15/100) — Total assets $40.45M and equity $10.94M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 2361.01 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 43/100 with 2/7 criteria passed.

NARI

Inari Medical, Inc.

$79.97

+0.00%

LIVN

LivaNova PLC

$65.14

+0.23%

ITGR

Integer Holdings Corporation

$87.94

-0.78%

IRMD

IRadimed Corporation

$93.05

-0.55%

FNA

Paragon 28, Inc.

$13.09

+0.00%

SRDX

Surmodics, Inc.

$42.98

+0.35%

NPCE

NeuroPace, Inc.

$15.61

+1.69%

OFIX

Orthofix Medical Inc.

$12.87

+1.18%